Clinical Trial Update: SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes [Phase 2, Phase 3]

View source ↗

Summary

This clinical trial update notes an ongoing Phase 2/3 study evaluating SGLT2 inhibitor therapy for cystic fibrosis-related diabetes, sponsored by the University…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis
• Cystic Fibrosis-related Diabetes

Drugs mentioned

• SGLT2 inhibitor

Snippet

Sponsor: University of Minnesota | Conditions: Cystic Fibrosis-related Diabetes, Cystic Fibrosis | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING